Updated on 2025/03/28

写真a

 
TSUBOTA Shoma
 
Organization
Graduate School of Medicine Program in Integrated Medicine Biological Chemistry Assistant Professor
Graduate School
Graduate School of Medicine
Undergraduate School
School of Medicine Department of Medicine
Title
Assistant Professor
External link

Degree 2

  1. Doctor of Philosophy (Medical Science) ( 2017.10   Nagoya University ) 

  2. Master of Medical Science ( 2013.3   Nagoya University ) 

Research Interests 4

  1. Neuroblastoma

  2. Cancer biology

  3. Molecular Biology

  4. 神経芽腫

Research Areas 1

  1. Life Science / Tumor biology

Research History 4

  1. Nagoya University   Department of Molecular Biology, Nagoya University Graduate School of Medicine   Assistant Professor

    2019.4

  2. 名古屋大学大学院医学系研究科分子生物学   助教

    2019.4

      More details

  3. 名古屋大学大学院医学系研究科分子生物学   研究員

    2017.4 - 2019.3

      More details

  4. Japan Society for Promotion of Science

    2014.4 - 2017.3

      More details

Education 1

  1. Nagoya University   Graduate School of Medicine   Program in Integrated Medicine

    2013.4 - 2017.3

      More details

 

Papers 18

  1. Combination of tumor necrosis factor-α and epidermal growth factor induces the adrenergic-to-mesenchymal transdifferentiation in SH-SY5Y neuroblastoma cells. Reviewed International journal Open Access

    Yue Huang, Shoma Tsubota, Nobuhiro Nishio, Yoshiyuki Takahashi, Kenji Kadomatsu

    Cancer science   Vol. 112 ( 2 ) page: 715 - 724   2021.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Neuroblastoma, a type of cancer that is common in children, is composed of two genetically clonal but epigenetically distinct cell types: mesenchymal (MES) and adrenergic (ADRN) types, controlled by super-enhancer-associated lineage-specific transcription factor networks. Mesenchymal-type cells are more migratory, resistant to chemotherapy, and prevalent in relapse tumors. Importantly, both cell types spontaneously transdifferentiate into one another, and this interconversion can be induced by genetic manipulations. However, the mechanisms of their spontaneous transdifferentiation and extracellular factors inducing this phenomenon have not yet been elucidated. Using a unique approach involving gene set enrichment analysis, we selected six ADRN and 10 MES candidate factors, possibly inducing ADRN and MES phenotypes, respectively. Treatment with a combination of 10 MES factors clearly induced the MES gene expression profile in ADRN-type SH-SY5Y neuroblastoma cells. Considering the effects on gene expression profile, migration ability, and chemoresistance, a combination of tumor necrosis factor alpha (TNF-α) and epidermal growth factor (EGF) was sufficient to synergistically induce the ADRN-to-MES transdifferentiation in SH-SY5Y cells. In addition, human neuroblastoma cohort analysis revealed that the expression of TNF and EGF receptors was strongly associated with MES gene expression signatures, supporting their important roles in transdifferentiation in vivo. Collectively, we propose a mechanism of neuroblastoma transdifferentiation induced by extracellular growth factors, which can be controlled in clinical situations, providing a new therapeutic possibility.

    DOI: 10.1111/cas.14760

    Open Access

    Web of Science

    Scopus

    PubMed

    researchmap

  2. Origin and initiation mechanisms of neuroblastoma Reviewed International journal

    Shoma Tsubota, Kenji Kadomatsu

    Cell and Tissue Research   Vol. 372 ( 2 ) page: 211 - 221   2018.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Springer Verlag  

    Neuroblastoma is an embryonal malignancy that affects normal development of the adrenal medulla and paravertebral sympathetic ganglia in early childhood. Extensive studies have revealed the molecular characteristics of human neuroblastomas, including abnormalities at genome, epigenome and transcriptome levels. However, neuroblastoma initiation mechanisms and even its origin are long-standing mysteries. In this review article, we summarize the current knowledge about normal development of putative neuroblastoma sources, namely sympathoadrenal lineage of neural crest cells and Schwann cell precursors that were recently identified as the source of adrenal chromaffin cells. A plausible origin of enigmatic stage 4S neuroblastoma is also discussed. With regard to the initiation mechanisms, we review genetic abnormalities in neuroblastomas and their possible association to initiation mechanisms. We also summarize evidences of neuroblastoma initiation observed in genetically engineered animal models, in which epigenetic alterations were involved, including transcriptomic upregulation by N-Myc and downregulation by polycomb repressive complex 2. Finally, several in vitro experimental methods are proposed that hopefully will accelerate our comprehension of neuroblastoma initiation. Thus, this review summarizes the state-of-the-art knowledge about the mechanisms of neuroblastoma initiation, which is critical for developing new strategies to cure children with neuroblastoma.

    DOI: 10.1007/s00441-018-2796-z

    Web of Science

    Scopus

    PubMed

    researchmap

  3. PRC2-Mediated Transcriptomic Alterations at the Embryonic Stage Govern Tumorigenesis and Clinical Outcome in MYCN-Driven Neuroblastoma Reviewed International journal Open Access

    Shoma Tsubota, Satoshi Kishida, Teppei Shimamura, Miki Ohira, Satoshi Yamashita, Dongliang Cao, Shinichi Kiyonari, Toshikazu Ushijima, Kenji Kadomatsu

    CANCER RESEARCH   Vol. 77 ( 19 ) page: 5259 - 5271   2017.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:AMER ASSOC CANCER RESEARCH  

    Pediatric cancers such as neuroblastoma are thought to involve a dysregulation of embryonic development. However, it has been difficult to identify the critical events that trigger tumorigenesis and differentiate them from normal development. In this study, we report the establishment of a spheroid culture method that enriches early-stage tumor cells from TH-MYCN mice, a preclinical model of neuroblastoma. Using this method, we found that tumorigenic cells were evident as early as day E13.5 during embryo development, when the MYC and PRC2 transcriptomes were significantly altered. Ezh2, an essential component of PRC2, was expressed in embryonic and postnatal tumor lesions and physically associated with N-MYC and we observed that H3K27me3 was increased at PRC2 target genes. PRC2 inhibition suppressed in vitro sphere formation, derepressed its target genes, and suppressed in situ tumor growth. In clinical specimens, expression of MYC and PRC2 target genes correlated strongly and predicted survival outcomes. Together, our findings highlighted PRC2-mediated transcriptional control during embryogenesis as a critical step in the development and clinical outcome of neuroblastoma. (C) 2017 AACR.

    DOI: 10.1158/0008-5472.CAN-16-3144

    Web of Science

    Scopus

    PubMed

    researchmap

  4. Identification of APPB1 as a substrate for anaplastic lymphoma kinase. International journal

    Yuji Suzuki, Shoma Tsubota, Kenji Kadomatsu, Kazuma Sakamoto

    Journal of biochemistry   Vol. 176 ( 5 ) page: 395 - 403   2024.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Anaplastic lymphoma kinase (ALK) is a well-known oncogene involved in various malignancies such as anaplastic large cell lymphoma, lung cancer and neuroblastoma. Several substrates for fused ALK have been identified and their biological functions have been described. However, the lack of a comprehensive identification of ALK substrates limits our understanding of the biological roles of receptor ALK. Thus, this study aimed to identify novel ALK substrates and characterize their biological functions. We screened the interactors of the kinase domain of receptor ALK using proximity-dependent biotin identification and identified 43 interactors. We narrowed down the candidates by evaluating whether these interactors were downstream of ALK in a neuroblastoma cell line, NB-1. Among these, we identified amyloid beta precursor protein binding family B member 1 (APBB1) as an ALK downstream molecule involved in NB-1 cell viability. Finally, we assessed the kinase-substrate relationship between ALK and APBB1 and found that ALK phosphorylated multiple tyrosine residues in APBB1 both in-cell and in-tube assays, with tyrosine 269 as a major target. In conclusion, we successfully identified a new substrate for receptor ALK. Our results may help further elucidate the molecular mechanism of ALK downstream signaling in neuroblastoma.

    DOI: 10.1093/jb/mvae055

    Web of Science

    Scopus

    PubMed

    researchmap

  5. Detecting and exploring kidney-derived extracellular vesicles in plasma. Open Access

    Shintaro Komatsu, Noritoshi Kato, Hiroki Kitai, Yoshio Funahashi, Yuhei Noda, Shoma Tsubota, Akihito Tanaka, Yuka Sato, Kayaho Maeda, Shoji Saito, Kazuhiro Furuhashi, Takuji Ishimoto, Tomoki Kosugi, Shoichi Maruyama, Kenji Kadomatsu

    Clinical and experimental nephrology   Vol. 28 ( 7 ) page: 617 - 628   2024.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Extracellular vesicles (EVs) have received considerable attention as ideal biomarkers for kidney diseases. Most reports have focused on urinary EVs, that are mainly derived from the cells in the urinary tract. However, the detection and the application of kidney-derived EVs in plasma remains uncertain. METHODS: We examined the kidney-derived small EVs (sEVs) in plasma that were supposedly released from renal mesangial and glomerular endothelial cells, using clinical samples from healthy controls and patients with kidney transplants. Plasma from healthy controls underwent ultracentrifugation, followed by on-bead flow cytometry, targeting α8 integrin, an antigen-specific to mesangial cells. To confirm the presence of kidney-derived sEVs in peripheral blood, plasma from ABO-incompatible kidney transplant recipients was ultracentrifuged, followed by western blotting for donor blood type antigens. RESULTS: Immunohistochemistry and immunoelectron microscopy confirmed α8 integrin expression in kidney mesangial cells and their sEVs. The CD9-α8 integrin double-positive sEVs were successfully detected using on-bead flow cytometry. Western blot analysis further revealed transplanted kidney-derived sEVs containing blood type B antigens in non-blood type B recipients, who had received kidneys from blood type B donors. Notably, a patient experiencing graft kidney loss exhibited diminished signals of sEVs containing donor blood type antigens. CONCLUSION: Our findings demonstrate the potential usefulness of kidney-derived sEVs in plasma in future research for kidney diseases.

    DOI: 10.1007/s10157-024-02464-z

    Open Access

    Scopus

    PubMed

    researchmap

▼display all

KAKENHI (Grants-in-Aid for Scientific Research) 4

  1. 神経芽腫の時期・細胞特異的な発生機構解明

    Grant number:22K07186  2022.4 - 2025.3

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    坪田 庄真

      More details

    Authorship:Principal investigator 

    Grant amount:\4290000 ( Direct Cost: \3300000 、 Indirect Cost:\990000 )

    小児がんの一つである神経芽腫は、様々なゲノム異常とエピゲノム異常が混在し、治療抵抗性から自然退縮まで表現型が極めて多様である。しかし、そもそもなぜ神経芽腫が発生するのか、特にがん化の時期や細胞特異性、神経芽腫を成り立たせる因子(発生に必須の遺伝子)については不明である。本研究では、独自の培養技術とシングルセル遺伝子発現解析の結果を活用し、マウス副腎組織を対象とした各種細胞タイプの選別、in vitroでのがん化誘導による神経芽腫の起源となる細胞(がん化する細胞タイプ)の同定、網羅的な遺伝子発現解析や介入実験を行い、神経芽腫の時期や細胞特異性に着目した発生機構の解明を目的とする。
    研究代表者は独自の細胞培養系(in vitro神経芽腫発生モデル)を用いて神経芽腫のがん化に時期特異性が存在するという予備データを得た。本研究は時期や細胞特異性に着目した神経芽腫の発生機構の解明を目的とし、将来的な新規治療法の開発に資する基盤を構築することを目指している。具体的には、(実験1)生後0日マウス副腎組織中に存在しがん遺伝子MYCNにより形質転換する細胞タイプの同定、(実験2)がん化細胞タイプの週齢別での存在確認、(実験3)がん化細胞タイプの週齢別の選別と遺伝子発現解析、(実験4)時期特異性を担う遺伝子の同定という実験項目について研究を進めている。昨年度、実験1について細胞表面抗原に対する抗体を用いた細胞選別を試したが、良い抗体がなく実験のセッティングに幾つか問題点が生じ、抗体を用いた細胞選別という方法は難しいと考えた。実験2については既に知られている神経芽腫の起源と推定されている副腎組織中の細胞タイプについて週齢別の存在をRNA-ISHで評価した。今年度は、当初の研究計画を変更し、各週齢のマウス副腎組織(0週、1週、2週、3週齢)と0週齢の副腎組織由来細胞をMYCNにより形質転換したスフェアを対象にシングルセル遺伝子発現解析を行った。時期特異的に消失する細胞タイプの存在を確認し、またMYCNにより形質転換したスフェア細胞の特徴付けを行った。さらに、レポーターマウスを用いた細胞単離と形質転換実験を組み合わせることで、概ねMYCNにより形質転換する細胞タイプの絞り込みができた。
    昨年度から少々遅れているが、実験1で当初予定していた表面抗原マーカーを用いた細胞選別で、想定通りに実験を遂行できなかった。その代案として、今年度はマウス副腎組織(0週、1週、2週、3週齢)と0週齢のマウス副腎組織由来細胞をMYCNにより形質転換したスフェアを対象にシングルセル遺伝子発現解析を行った。副腎組織の週齢別の比較によって、神経芽腫の起源細胞だと推測されている神経芽細胞は週齢が経つにつれて消失していくことが分かった。これについては昨年度に実施したRNA-ISHの結果と合致した。一方で、MYCNにより形質転換したスフェアの遺伝子発現を副腎組織と比較することで、MYCNにより形質転換した起源となる細胞の候補を明らかにした。これまで知られていたようにチロシン水酸化酵素(Th)を発現していることが分かった。またTh-EGFPレポーターマウスを用いた細胞選別によりMYCNにより形質転換する細胞はTh陽性細胞であることが明らかとなった。興味深いことに、この細胞タイプは神経芽細胞の特徴よりもクロム親和性細胞の特徴を持つということが明らかとなった。神経芽腫は神経芽細胞由来だと考えられていたが、クロム親和性細胞である可能性も出てきた。
    当初予定していた実験1から3については概ね良好な結果を得ることができたが、神経芽腫の起源が神経芽細胞なのかクロム親和性細胞なのか新たな疑問が生じてしまう結果となった。これについてシングルセル遺伝子発現解析結果の精査を行うとともに、神経芽細胞もしくはクロム親和性細胞を特異的に分取できる新たなレポーターマウスの導入を検討する。さらにシングルセル遺伝子発現解析を引き続き行い、細胞や時期特異性についてMYCNと強調的に働くと考えられる遺伝子について同定を試みる。

    researchmap

  2. Mechanism of neuroblastoma development caused by epigenetic abnormalities induced by MYCN and EZH2

    Grant number:20K16355  2020.4 - 2022.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Early-Career Scientists

    Tsubota Shoma

      More details

    Authorship:Principal investigator 

    Grant amount:\4290000 ( Direct Cost: \3300000 、 Indirect Cost:\990000 )

    Neuroblastoma is a childhood cancer and caused by MYCN, a well-known oncogene. We have been working to elucidate the mechanism of oncogenesis by MYCN and the epigenomic regulator EZH2. In this study, we could not reproduce the previous report that the MB2 domain of MYCN is bound to EZH2. However, we obtained data suggesting that the MB2 domain may be essential for the transforming ability of MYCN. In addition, MYCN and EZH2 co-localized at the promoter sites of MYCN target genes in the genome, suggesting the existence of a new regulatory mechanism for gene expression by MYCN and EZH2.

    researchmap

  3. Mechanism of neuroblastoma development by MYCN-PRC2 mediated epigenomic aberrations

    Grant number:18K15208  2018.4 - 2020.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Early-Career Scientists

    Tsubota Shoma

      More details

    Authorship:Principal investigator 

    Grant amount:\4160000 ( Direct Cost: \3200000 、 Indirect Cost:\960000 )

    Neuroblastoma is a childhood cancer, and is caused by the well-known oncogene, MYCN. The applicant previously reported that EZH2, an epigenomic regulator, is important for MYCN-induced neuroblastoma development, that MYCN binds to EZH2, and that inhibition EZH2 function can prevent neuroblastoma growth. In this study, we investigated whether the binding of MYCN to EZH2 is essential for the development of neuroblastoma. Unfortunately, we could not reproduce the previous report that a part of MYCN is required for the binding of EZH2 in the first place, so we did not achieve our goal within the study period.

    researchmap

  4. MYCN-Tgマウスにおける神経芽腫発生の運命決定機構の解明

    Grant number:14J00157  2014.4 - 2017.3

    日本学術振興会  科学研究費助成事業  特別研究員奨励費

    坪田 庄真

      More details

    本研究は、小児がんの一つである神経芽腫のMYCN-Tgマウスモデルにおける腫瘍発生の運命決定機構の解明である。特に腫瘍形成初期イベントに着目し、MYCN-Tgマウスの組織とSpheroid cultureによって得られた細胞を対象に網羅的解析を行い、エピゲノム制御分子であるPRC2 が神経芽腫の発生初期において重要な分子の一つであることを明らかにした。PRC2の中でもヒストンメチル基転移酵素のEzh2が、ヒストンH3の27番目のリジンをトリメチル化(H3K27me3)しターゲット分子の発現を抑制する。
    MYCN-Tg由来Sphereでは野生型由来Sphereに比べ、PRC2ターゲット遺伝子の発現が低下していた。ゲノムレベルでのH3K27me3修飾状態を調べるためにChIP-sequencingを行った。その結果、MYCN-Tg由来SphereではPRC2ターゲット分子の遺伝子領域(特にプロモーター)でH3K27me3が増加していた。PRC2ターゲット遺伝子の発現低下が、H3K27me3レベルの増加によるものであることが示唆された。
    Ezh2に対するshRNAとそのヒストンメチル基転移活性を阻害する薬を用い介入実験を行った。その結果、ノックダウン及び薬のどちらもin vitroでの細胞増殖を著しく抑制した。また、阻害剤はin vivoにおいてもTH-MYCNマウスの腫瘍形成を著しく阻害した。神経芽腫においてEzh2がその生存に必須であることを示唆している。
    最後に、約500例のヒト神経芽腫の発現解析データを調べた結果、より悪性度が高い患者でPRC2ターゲットの発現が低く、予後不良と相関していることが明らかになった。
    これまで神経芽腫におけるPRC2の役割、特に腫瘍発生の初期に関わっているという報告はなく、新規な知見を得ることができた。

    researchmap